GEN Exclusives

More »

GEN News Highlights

More »
Aug 18, 2009

Geron’s hESC Therapy for Spinal Cord Injury Has Been Placed on Hold

  • FDA has put a clinical hold on Geron’s human embryonic stem cell (hESC) therapy for spinal cord injury, because it is reviewing nonclinical animal data submitted after the IND filing. The IND covers the study of GRNOPC1 in neurologically complete, subacute spinal cord injury.

    The new data submitted to the FDA was derived from studies to enable dose escalation and application of the product to other neurodegenerative diseases. The firm adds that it has also been performing additional product characterization and conducting further animal studies.

    In January Geron was given the go-ahead to initiate a Phase I trial in patients with spinal cord injury. GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury, the firm explains.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?